LDS/Medical Tests/Endometrial Carcinoma Gene Mutation Panel, NGS

Endometrial Carcinoma Gene Mutation Panel, NGS

Endometrial cancer is the uncontrolled proliferation of the inner lining of the uterus (endometrium). It is the most common gynecologic malignancy in developed countries and the sixth most common cancer in women worldwide, with ~417,000 new cases and ~97,000 deaths annually (GLOBOCAN 2020). Most patients are diagnosed post-menopause, with a median age of diagnosis at 60, however, cases in younger women have been rising.

Prognosis strongly depends on stage with 5-year overall survival for early-stage endometrial carcinoma being >80%, but falls below 20% in stage IV. It has been estimated that around 67% of the patients present with an early stage disease. Therefore, it is very crucial not to miss the diagnosis of these early stage patients so as to ensure longer survival. Molecular alterations significantly influence both prognosis and therapy, and the TCGA (The Cancer Genome Atlas) classification has revolutionized risk stratification.

Various germline mutations have been linked to the biological diversity and occurrence of endometrial cancer and Lynch syndrome (EPCAM gene deletions). It has been shown that Lynch syndrome accounts for 3% of total endometrial cancer incidences. Few studies have also reported the positive association of PTEN and BRCA gene mutations in endometrial cancer.

The endometrial carcinoma NGS panel evaluates variants and mutations in the genes implicated in endometrial carcinoma, including ATM, ATR, BRCA1, BRCA2, CDK12, CTNNB1, EPCAM, ERBB2 (HER2), FBXW7, L1CAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, POLE, PPP2R1A, and TP53. Additionally, the panel also tests for the status of microsatellite instability for determining the efficacy of immune checkpoint inhibitors.

  • As an aid in the diagnosis of endometrial cancer
  • Identification of Lynch syndrome in patients and family members
  • For the prediction of future risk of endometrial cancer
  • Therapy selection and disease management
Results are provided as an integrated report summarizing detected variants, MSI status, and molecular subtype. Detected pathogenic variants are correlated with diagnostic, prognostic, and therapeutic implications. Variants of uncertain significance (VUS) are reported but should not be used for therapy decisions without further evidence. No pathogenic variants detected does not exclude disease—results must be interpreted in clinical and histopathological context.

No pathogenic variant detected (Negative for mutation analyzed)

Next-generation sequencing (NGS) of targeted panel genes. MSI testing incorporated into analysis.

FFPE tumor tissue (≥20% tumor nuclei required).

Alternatives: whole blood or saliva (for germline mutation analysis).

Stability

  • FFPE: Stable at room temperature indefinitely.

Stability (Blood)

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
Immunohistochemistry (IHC): MLH1, MSH2, MSH6, PMS2 for mismatch repair protein expression. Serum markers: CA-125 (advanced disease), hCG (to rule out trophoblastic disease). Other molecular panels: Lynch syndrome multigene germline testing, PTEN mutation analysis. Histologic correlation: Endometrial biopsy/Pap smear.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login